Clinical Trial

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-05; most recent amendment 2026-02-24.
Status change: Recruiting → Completed 2026-02-24
Status change: Not Yet Recruiting → Recruiting 2025-08-15
Trial Details
NCT Number NCT07018492
Lead Sponsor Shionogi
Conditions Hepatic Impairment
Enrollment 32 participants
Start Date 2025-08-30
Primary Completion 2025-11-26 (estimated)
Study Completion 2025-11-26 (estimated)
Updated on ClinicalTrials.gov 2026-02-27